Your browser doesn't support javascript.
loading
CD4+ T helper 2 cells suppress breast cancer by inducing terminal differentiation.
Boieri, Margherita; Malishkevich, Anna; Guennoun, Ranya; Marchese, Emanuela; Kroon, Sanne; Trerice, Kathryn E; Awad, Mary; Park, Jong Ho; Iyer, Sowmya; Kreuzer, Johannes; Haas, Wilhelm; Rivera, Miguel N; Demehri, Shadmehr.
Afiliação
  • Boieri M; Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Malishkevich A; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Guennoun R; Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Marchese E; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Kroon S; Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Trerice KE; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Awad M; Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Park JH; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Iyer S; Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Kreuzer J; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Haas W; Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Rivera MN; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Demehri S; Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
J Exp Med ; 219(7)2022 07 04.
Article em En | MEDLINE | ID: mdl-35657353
ABSTRACT
Cancer immunology research is largely focused on the role of cytotoxic immune responses against advanced cancers. Herein, we demonstrate that CD4+ T helper (Th2) cells directly block spontaneous breast carcinogenesis by inducing the terminal differentiation of the cancer cells. Th2 cell immunity, stimulated by thymic stromal lymphopoietin, caused the epigenetic reprogramming of the tumor cells, activating mammary gland differentiation and suppressing epithelial-mesenchymal transition. Th2 polarization was required for this tumor antigen-specific immunity, which persisted in the absence of CD8+ T and B cells. Th2 cells directly blocked breast carcinogenesis by secreting IL-3, IL-5, and GM-CSF, which signaled to their common receptor expressed on breast tumor cells. Importantly, Th2 cell immunity permanently reverted high-grade breast tumors into low-grade, fibrocystic-like structures. Our findings reveal a critical role for CD4+ Th2 cells in immunity against breast cancer, which is mediated by terminal differentiation as a distinct effector mechanism for cancer immunoprevention and therapy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Vacinas Anticâncer Limite: Female / Humans Idioma: En Revista: J Exp Med Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Vacinas Anticâncer Limite: Female / Humans Idioma: En Revista: J Exp Med Ano de publicação: 2022 Tipo de documento: Article